Agomab raises $100 million to advance fibrosis-focused pipeline
11 Oct 2023
Phase 1Phase 2Clinical ResultFinancial StatementPROTACs
Agomab Therapeutics on Wednesday closed a Series C financing round worth $100 million, which the company will use to advance its fibrosis-focused pipeline led by AGMB-129. Chief executive Tim Knotnerus said “we…have secured the funding required to conduct clinical studies for multiple drug candidates.”
The company recently started the Phase IIa STENOVA study of AGMB-129 - a gut-restricted small-molecule inhibitor of ALK5 – in patients with fibrostenosing Crohn’s disease. Earlier this year, Agomab reported Phase I results showing that single- and multiple-dosing of the oral drug was safe and well-tolerated and confirming gastro-intestinal (GI)-restricted exposure.
In addition, the proceeds of the financing will be used to advance Agomab’s portfolio of growth factor-targeting drug candidates, including AGMB-447, a small-molecule lung-restricted inhibitor of ALK5 for the treatment of idiopathic pulmonary fibrosis, and the cMET agonistic antibodies AGMB-101 and AGMB-102 for the treatment of fibrotic and degenerative disorders. The company said the funds will also allow “strategic expansion.”
The financing round was led by Fidelity Management & Research Company with participation from EQT Life Sciences, Canaan and KKR’s Dawn Biopharma. In conjunction with the funding, EQT’s Felice Verduyn - van Weegen will join Agomab’s board.
In 2019, Agomab raised €21 million ($22.3 million) in a Series A financing, pulling in $74 million via a Series B round in 2021, which was expanded the following year by $40.5 million.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.